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Abstract
Accelerated atherosclerosis, increased cardiovascular morbidity and mortality have been associated with rheumatoid arthritis 
(RA) and ankylosing spondylitis (AS). Vascular function, clinical and laboratory markers and the effects of anti-TNF therapy 
were assessed in arthritides. Fifty-three 53 patients including 36 RA patients treated with either etanercept (ETN) or cer-
tolizumab pegol and 17 AS patients treated with ETN were included in a 12-month follow-up study. Ultrasonography was 
performed to determine flow-mediated vasodilation (FMD), common carotid intima-media thickness (ccIMT) and arterial 
pulse-wave velocity (PWV) in all patients. All assessments were performed at baseline and 6 and 12 months after treatment 
initiation. A significant improvement of brachial artery FMD was observed after 6 months (p = 0.004). A tendency of FMD 
improvement was also observed after 12 months (p = 0.065). ccIMT did not change throughout the year. PWV significantly 
improved after 12 months (p = 0.034). Higher baseline ccIMT (p = 0.009) and PWV (p = 0.038) were associated with clinical 
non-response (cNR) versus response (cR) to biologics. Multiple analysis confirmed the association of baseline ccIMT with 
age (p = 0.003) and cNR (p = 0.009), as well as that of baseline PWV with age at diagnosis (p = 0.022) and current chest pain 
(p = 0.004). Treatment itself determined the 12-month changes in FMD (p = 0.020) and PWV (p = 0.007). In a mixed cohort 
of RA and AS patients, TNF inhibition improved or stabilized vascular pathophysiology. Inflammation may be associated 
with FMD, while, among others, cNR may influence vascular function.
Keywords Rheumatoid arthritis · Ankylosing spondylitis · Atherosclerosis · Cardiovascular disease · Flow-mediated 
vasodilation · Pulse-wave velocity · Carotid intima-media thickness
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ACPA  Anti-citrullinated protein antibody
AIx  Augmentation Index
AS  Ankylosing spondylitis
BASDAI  Bath Ankylosing Spondylitis Disease Activity 
Index
ccIMT  Common carotid intima-media thickness
CCP  Cyclic citrullinated peptide
cNR  Clinical non-response
cR  Clinical response
CRP  C-reactive protein
CV  Cardiovascular
CVD  Cardiovascular disease
CZP  Certolizumab pegol
DAS  Disease activity score
ETN  Etanercept
EULAR  European League Against Rheumatism
FMD  Flow-mediated vasodilation
PWV  Pulse-wave velocity
RA  Rheumatoid arthritis
RF  Rheumatoid factor
SC  Subcutaneous
TNF  Tumor necrosis factor
Introduction
Arthritides, such as rheumatoid arthritis (RA) and ankylos-
ing spondylitis (AS) have been associated with accelerated, 
inflammatory atherosclerosis, as well as increased cardio-
vascular (CV) morbidity and mortality [1–4]. It is crucial 
Rheumatology
INTERNATIONAL 
 * Zoltán Szekanecz 
 szekanecz.zoltan@med.unideb.hu
 http://www.rheumatology.hu
Extended author information available on the last page of the article
 Rheumatology International
1 3
to detect CV abnormalities early, possibly in the preclinical 
phase of CV disease (CVD) [1]. Indeed, non-invasive ultra-
sound-based techniques, in addition to clinical and labora-
tory biomarkers, may be suitable to assess preclinical vascu-
lar pathophysiology in RA and AS [1, 5]. Early endothelial 
dysfunction, overt atherosclerosis and increased arterial 
stiffness are indicated by abnormal endothelium-dependent, 
flow-mediated vasodilation (FMD) of the brachial artery, 
common carotid intima-media thickness (ccIMT) and carotid 
plaques, as well as arterial pulse-wave velocity (PWV), 
respectively [2, 5]. These preclinical abnormalities predict 
the development of subsequent CV events in arthritides [1, 
2, 5].
Systemic inflammation associated with RA and AS is the 
major driver of atherosclerosis and CVD in these diseases 
[1]. Pro-inflammatory cytokines, such as tumour necrosis 
factor α (TNF-α) is highly involved in the pathogenesis 
of RA-related atherosclerosis [6]. It is not surprising that 
the control of inflammation by targeted therapies includ-
ing TNF-α inhibitors may dampen atherosclerosis and may 
decrease CV morbidity and mortality in inflammatory arthri-
tis [7–10], especially in patients who respond to TNF inhibi-
tion [7, 8]. With respect to surrogate markers, anti-TNF bio-
logics may improve or at least stabilize vascular morphology 
and function including FMD [7, 11–17], ccIMT [7, 13, 16, 
18–20] and PWV [7, 21–25].
In this study, we wished to determine the effects of one-
year anti-TNF therapy on FMD, ccIMT and PWV. We also 
wished to determine the predictors of these parameters at 
baseline, as well as the determinants on one-year change in 
these parameters. This study may improve our understanding 
of vascular pathophysiology in RA and AS.
Patients and methods
Patients
Fifty-three patients with inflammatory arthritis (36 RA 
and 17 AS) selected for the initiation of anti-TNF therapy 
but unselected for CVD were enrolled in the study. Patient 
characteristics are seen in Table 1. The cohort included 34 
women and 19 men with mean age of 52.0 ± 12.1 (range 
24–83) years. Mean disease duration was 8.5 ± 7.9 (range 
1–44) years, while the mean age at diagnosis was 43.5 ± 12.1 
(range 23–62) years. Exclusion criteria included untreated, 
unstable hypertension (blood pressure > 140/90 mmHg), 
diabetes mellitus, current inflammatory disease other than 
RA or AS, infectious disease or renal failure (serum creati-
nine ≥ 117 mmol/l). None of the patients received aspirin, 
clopidogrel, heparin or warfarin or vasoactive drugs at the 
time of inclusion. Patients with active disease were recruited 
prior to initiating a biological therapy. All patients started on 
an anti-TNF therapy at baseline and received the same bio-
logical treatment at one year. Among the 36 RA patients, 20 
received etanercept (ETN) 50 mg/week subcutaneous (SC) 
and 16 received certolizumab pegol (CZP) (400 mg at 0, 2 
and 4 weeks, and thereafter 200 mg twice weekly SC). Alto-
gether 18 RA patients were treated with ETN and 13 with 
CZP in combination with methotrexate (MTX). The other 
Table 1  Patient characteristics
RA AS Total
n 36 17 53
Female:male 31:5 3:14 34:19
Age (mean ± SEM)(range), years 55.9 ± 9.8 (35–83) 43.6 ± 12.4 (24–72) 52.0 ± 12.1 (24–83)
Disease duration (mean ± SEM) (range), years 9.1 ± 8.3 (1–44) 7.2 ± 7.0 (1–26) 8.5 ± 7.9 (1–44)
Age at diagnosis 47.0 ± 8.7 (28–62) 36.4 ± 11.6 (23–50) 43.5 ± 12.1 (23–62)
Smoking (current) 7 7 14
Positive CV history 8 1 9
Current, stable hypertension 3 0 3
Diabetes mellitus 1 0 1
Periodontitis (current) 10 5 15
Tooth loss (current) 14 7 21
Current low-dose Corticosteroids 12 2 14
RF positivity, n (%) 26 (72) – –
ACPA positivity, n (%) 21 (58) – –
DAS28 (baseline) (mean ± SEM) 5.00 ± 0.86 – –
BASDAI (baseline) (mean ± SEM) – 5.79 ± 1.19 –
Treatment (ETN, CZP) 20 ETN, 16 CZP 17 ETN 37 ETN, 16 CZP
Biologic in combination with MTX 18 ETN, 13 CZP – 18 ETN, 13 CZP
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patients received monotherapy. All 17 AS patients received 
50 mg/week ETN monotherapy SC. RA patients did not take 
DMARDs other than MTX. Altogether 12 RA and 2 AS 
patients currently took low-dose (< 6 mg/day) methylpred-
nisolone (Table 1).
Disease activity was determined by DAS28 and BAS-
DAI in RA and AS, respectively. Clinical responder (cR vs 
cNR) status was determined after 12 months of treatment 
with either ETN or CZP by the EULAR response criteria 
originally reported by Van Gestel et al. [26] and described 
by us before [27].
The study was approved by the Hungarian Scien-
tific Research Council Ethical Committee (Approval no. 
14804–2/2011/EKU). Written informed consent was 
obtained from each patient and assessments were carried 
out according to the Declaration of Helsinki.
Clinical assessment
First, a detailed medical history was taken. We inquired for 
the history of CVD, as well as current smoking, the experi-
ence of chest pain resembling angina pectoris, hypertension 
and diabetes mellitus during the last 2 years prior to the start 
of this study by a questionnaire (Table 1). Further clinical 
assessments including physical examination were performed 
at baseline, and after 3, 6 and 12 months of therapy. At base-
line, RA patients had a mean DAS28 of 5.00 ± 0.86, while 
AS patients exerted mean BASDAI of 5.79 ± 1.19 (Table 1).
Laboratory measurements
Serum high sensitivity C reactive protein (hsCRP; nor-
mal: ≤ 5  mg/l) and IgM rheumatoid factor (RF; nor-
mal: ≤ 50  IU/ml) were measured by quantitative neph-
elometry (Cobas Mira Plus-Roche), using CRP and RF 
reagents (both Dialab). ACPA (anti-CCP) autoantibodies 
were detected in serum samples using a second-generation 
Immunoscan-RA CCP2 ELISA test (Euro Diagnostica; nor-
mal: ≤ 25 IU/ml). The assay was performed according to the 
manufacturer’s instructions.
Assessment of vascular physiology by ultrasound
Brachial artery FMD was assessed as described before [2, 
28, 29]. In brief, ultrasound examination was performed on 
the right arm using 10 MHz linear array transducer (ultra-
sound system: HP Sonos 5500) by a single trained sonog-
rapher after 30 min rest in a temperature-controlled room 
(basal value for FMD). A B-mode longitudinal section was 
obtained from the brachial artery above the antecubital 
fossa. To assess FMD, reactive hyperaemia was induced by 
the release of a pneumatic cuff around the forearm inflated 
to suprasystolic pressure for 4.5 min. After deflation the 
maximal flow velocity and the arterial diameter was 90 s 
long continuously recorded. Flow velocities, the baseline 
diameter, as well as FMD were ECG gated and detected 
offline. FMD values were expressed as % change from base-
line (resting) value.
The ccIMT measurements were carried out as described 
before [2, 29, 30]. Briefly, a duplex ultrasound system (HP 
Sonos 5500, 10 MHz linear array transducer) was used to 
assess the common carotid arteries by a single observer. 
Longitudinal high-resolution B-mode ultrasound scan was 
employed over both right and left common carotid arteries 
and were R-synchronized and recorded. The offline measure-
ments were performed 1 cm proximal to the carotid bulb in 
the far wall. ccIMT was defined as the distance between the 
first and second echogenic lines from the lumen taking the 
average of 10 measurements on both sides. ccIMT values 
were expressed in mm.
With respect to arterial stiffness, PWV was calculated 
automatically by a TensioClinic arteriograph system (Ten-
siomed Ltd, Budapest, Hungary) as the quotient of the dis-
tance between the jugular fossa and symphysis as described 
before [29, 31]. If an artery is elastic, PWV is low. With 
decreased arterial elasticity, PWV rises. The arteriograph 
assesses this parameter from the oscillometric data obtained 
from the 35 mmHg suprasystolic pressure of the brachial 
artery. To obtain reproducible results, the patient had to rest 
in a supine position for at least 10 min before the assessment 
in a quiet room. PWV is expressed in m/s. Reproducibility 
of the three techniques expressed in intraclass correlation is 
included in the Statistical analysis section.
Statistical analysis
Statistical analysis was performed using SPSS version 22.0 
(IBM) software. Data are expressed as the mean ± SD for 
continuous variables and percentages for categorical vari-
ables. The distribution of continuous variables was evaluated 
by Kolmogorov–Smirnov test. Independent and paired two-
tailed t test were used assessed the differences. Nominal var-
iables were compared between groups using the chi-squared 
or Fisher’s exact test, as appropriate. Correlations were 
determined by Pearson’s analyses. Univariate and multiple 
regression analysis using the stepwise method were applied 
to investigate independent associations between angiogenic 
biomarkers (dependent variables) and other clinical, labora-
tory and imaging parameters (independent variables). The β 
standardized linear coefficients showing linear correlations 
between two parameters were determined. The B (+ 95% 
CI) regression coefficient indicated independent associa-
tions between dependent and independent variables during 
changes. Repeated measures analysis of variance (RM-
ANOVA) was performed to determine the additional effects 
of multiple parameters on changes of vascular imaging 
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markers between baseline and 12 months. The dependent 
variables were FMD, ccIMT and PWV. Partial η2 is given 
as an indicator of effect size, with values of 0.01 suggesting 
small, 0.06 medium and 0.14 large effects. Three related 
samples were compared by the Friedman test. The reliabil-
ity was tested by inter-item correlation and intraclass cor-
relation (ICC). With respect to the FMD, ccIMT and PWV 
tests, ICC = 0.470; F test value: 1.887; p = 0.001. The power 
was estimated with G-Power software. p values < 0.05 were 
considered significant.
Results
Effects of anti‑TNF therapy on clinical activity, 
inflammation and clinical response in RA and AS
In RA (n = 36), one-year ETN or CZP therapy signifi-
cantly improved DAS28 (12 months: 3.02 ± 0.96; baseline: 
5.00 ± 0.86; p < 0.001) (data not shown). Similarly, in AS 
(n = 17), BASDAI significantly decreased from 5.79 ± 1.19 
(baseline) to 1.86 ± 1.04 after 12 months of ETN treatment 
(p < 0.001) (data not shown).
With respect to inflammation, in the mixed arthri-
tis cohort, CRP significantly decreased as early as after 
3 months of treatment (7.57 ± 12.02 mg/l) compared to 
baseline (14.88 ± 17.09 mg/l; p < 0.001). This effect was 
even more pronounced after 6 months (6.79 ± 9.52 mg/l; 
p < 0.001) and 12 months of therapy (6.49 ± 7.60 mg/l; 
p < 0.001) (data not shown).
As described above, cR and cNR status of the patients 
was also determined [26, 27]. Altogether 34 patients (64%) 
were cR and 19 (36%) were cNR (data not shown).
Effects of TNF inhibition on vascular 
pathophysiology
Although, as mentioned in the Discussion, FMD, ccIMT 
and PWV do not have “normal values”, baseline FMD was 
lower, while ccIMT and PWV were higher in RA compared 
to AS reflecting more pronounced pathology in RA com-
pared to AS (data not shown).
In the mixed cohort of 53 arthritis patients, brachial 
artery FMD significantly improved after 6 months of anti-
TNF therapy (10.01 ± 5.26%) versus baseline (7.67 ± 4.40%; 
p = 0.004) (Fig. 1). This improvement was also observed, 
however, non-significantly, after 12 months (9.70 ± 4.91%; 
p = 0.065) (Fig. 1). ccIMT remained stable showing no 
significant progression after 6 months (0.59 ± 0.11 mm; 
p = 0.09) and 12  months (0.59 ± 0.12  mm; p = 0.240) 
Fig. 1  Effects of 1-year anti-TNF therapy on FMD (a), ccIMT (b) and PWV (c) in RA and AS. Asterisks indicate significant changes (p < 0.05)
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compared to baseline (0.540 ± 0.087  mm) (Fig.  1). 
PWV reflecting arterial stiffness slightly improved after 
6  months (7.32 ± 1.63  m/s; p = 0.866) versus baseline 
(7.48 ± 1.98 m/s). This improvement was significant after 
12 months (7.17 ± 2.59 m/s; p = 0.034) (Fig. 1). We also 
assessed the effects of ETN vs CZP separately and we did 
not find any differences in FMD, ccIMT or PWV at baseline 
and after 6 and 12 months (data not shown).
Correlations of markers of vascular pathophysiology 
with clinical response and other parameters
When nominal variables were evaluated, patients with a his-
tory of CVD had significantly higher ccIMT after 6 months 
(0.60 ± 0.07 mm vs 0.55 ± 0.09 mm; p = 0.045) and after 
12 months (0.61 ± 0.12 mm vs 0.54 ± 0.10 mm; p = 0.033), 
as well as higher PWV at baseline (8.34 ± 2.29  m/s 
vs 6.62 ± 1.13  m/s; p = 0.005) and after 6  months 
(7.94 ± 1.86 m/s vs 6.66 ± 1.23 m/s; p = 0.012) compared 
to patients with negative CVD history (data not shown). 
Moreover, patients currently experiencing chest pain also 
had significantly higher baseline PWV (8.64 ± 2.47 m/s 
vs 7.59 ± 2.00  m/s; p = 0.017) versus those who never 
had chest pain previously (data not shown). Patients with 
hypertension had higher 12-month ccIMT (0.62 ± 0.11 mm 
vs 0.55 ± 0.11  mm; p = 0.050) and baseline PWV 
(8.36 ± 2.24 m/s vs 6.88 ± 1.56 m/s; p = 0.016) compared to 
those with normal blood pressure (data not shown).
When comparing vascular pathophysiology with clinical 
responsiveness, cNR patients had significantly higher base-
line ccIMT (0.60 ± 0.08 mm vs 0.52 ± 0.08 mm; p = 0.009); 
6-month ccIMT (0.64 ± 0.14  mm vs 0.56 ± 0.09  mm; 
p = 0.023) and baseline PWV (8.47 ± 2.62  m/s vs 
7.08 ± 1.55 m/s; p = 0.038) compared to cR patients (data 
not shown).
When vascular imaging parameters were correlated with 
each other, baseline and 12-month ccIMT correlated with 
baseline and 12-month PWV, respectively (data not shown).
With respect to simple correlations of vascular imaging 
and other parameters, baseline and 12-month ccIMT, as well 
as 12-month PWV significantly correlated with age. Base-
line ccIMT and PWV, as well as 12-month ccIMT and PWV 
also correlated with age at diagnosis of RA. Baseline FMD, 
as well as baseline and 12-month PWV showed a positive 
correlation with baseline CRP (Table 2).
Results of the univariate and multiple analyses are indi-
cated in Table 3. In the univariate analysis of the mixed 
RA + AS population, baseline FMD was determined by 
baseline CRP (p = 0.040). The predictors of baseline ccIMT 
were age, age at diagnosis and cNR vs cR status (p < 0.05). 
ccIMT after 12 months of treatment was determined by age, 
age at diagnosis, as well as the history of CVD (p < 0.05). 
Age at diagnosis, history of CVD and current hypertension, 
current chest pain and cNR vs cR status predicted baseline 
PWV (p < 0.05). Finally, 12-month PWV was determined by 
age and age at diagnosis (p < 0.001) (Table 3).
The multiple analysis of the RA + AS population con-
firmed the significant association of baseline ccIMT with 
age (p = 0.003) and cNR vs cR status (p = 0.009). ccIMT 
after 12 months of treatment was also associated with age 
(p < 0.001). Baseline PWV was determined by age at diag-
nosis (p = 0.022) and by current chest pain (p = 0.004), while 
12-month PWV showed association with age (p < 0.001) 
(Table 3).
When RA and AS patients were analyzed separately, 
according to the univariate analysis, the disease itself (RA 
vs AS) had a significant effect on ccIMT and PWV. How-
ever, in the multiple analysis we could not demonstrate this, 
therefore, the disease itself is not an independent prognostic 
factor for vascular pathophysiology (Table 3).
Finally, RM-ANOVA analysis was performed in the 
RA + AS mixed population to assess the determinants of 
12-month changes in vascular imaging parameters. Anti-
TNF treatment itself determined the changes of FMD 
(p = 0.020), ccIMT (p = 0.024) and PWV (p = 0.007) from 
baseline to 12-months. In addition, treatment exerted com-
bined effects with cR (p = 0.045) on changes in FMD. More-
over, treatment and age had a combined effect of changes in 
PWV (p = 0.003) (Table 4).
Discussion
First, as expected, anti-TNF therapy was clinically effective 
in both RA and AS as indicated by significant decreases of 
DAS28 and BASDAI, respectively. Altogether two-third of 
the patients responded to treatment (cR).
Ultrasound-based imaging may enhance risk CV strati-
fication in RA and AS [2, 3, 5, 20, 29, 32, 33] and, as also 
Table 2  Significant correlations between markers of vascular patho-
physiology and other parameters in the RA + AS population
See text for abbreviations and explanations
Age Age at diagnosis CRP-0 CRP-12
FMD-0 R = 0.318
p = 0.040
ccIMT-0 R = 0.449 R = 0.350 R = 0.403
p = 0.003 p = 0.023 p = 0.008
ccIMT-12 R = 0.477 R = 0.399
p = 0.001 p = 0.005
PWV-0 R = 0.351 R = 0.416
p = 0.023 p = 0.020
PWV-12 R = 0.571 R = 0.503 R = 0.411
p < 0.001 p < 0.001 p = 0.022
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recommended by EULAR, may be used for this purpose [1]. 
Ultrasound may have higher value during the assessment of 
CV risk than coronary calcium content determination [32]. 
There are no “normal values” for FMD, ccIMT and PWV in 
RA and AS due to the heterogeneity of patient populations 
and methodology. However, in various studies, FMD was 
4.6–7.7% in active, 8.6–13.5% in anti-TNF treated arthritis 
patients and 8.3–14.9% in healthy controls [2, 3, 12, 14, 
15]. Similarly, ccIMT was 0.63–0.76 mm, 0.62–0.68 mm 
and 0.54–0.62 mm in active, biologic-treated patients and 
controls, respectively [2, 3, 7, 13, 33, 34]. In a meta-analysis 
from 22 studies on 1384 RA patients and 1147 controls, the 
mean ccIMT values were 0.71 and 0.62 mm, respectively 
[34]. Moreover, when RA patients with and without CV 
events were compared, most CV events occurred in patients 
with ccIMT > 0.91 [33]. Finally, PWV was 8.3–8.6 m/s, 
7.5–7.7 m/s and 7.5–8.0 m/s in active, anti-TNF-treated 
patients and controls, respectively [3, 7, 22, 23]. In a recent 
meta-analysis of 10 studies and 208 patients, anti-TNF treat-
ment improved PWV by a mean 0.53 m/s [21].
The magnitude of FMD [7, 11–17], ccIMT [7, 13, 16, 
18–20] and PWV values [7, 21–25] before and after treat-
ment was similar to previously reported ones. TNF inhi-
bition resulted in a transiently significant improvement in 
FMD by 6 months. A tendency for improvement was also 
observed after one year. Biologics may inhibit the develop-
ment and progression of atherosclerosis and lower the inci-
dence of CV events in arthritides [7-10]. In a number of 
studies, biologics, mostly infliximab, resulted in an increase 
in FMD [11–16, 35] which, in few studies, was transient 
[14]. There were only a few long-term studies lasting more 
than one year [12]. Improvement in FMD was usually asso-
ciated with clinical response to biologics [12]. ccIMT did 
not change during the course of biological therapy. Similar 
results were published by some other groups in RA and AS 
[13, 16, 19]. One group reported improvement of ccIMT 
upon treatment with various biologics after one year [18]. 
We found that ccIMT may improve upon anti-TNF therapy 
in early RA [35]. Again, the improvement of carotid athero-
sclerosis was associated with clinical efficacy [18]. Without 
treatment, carotid atherosclerosis may progress over time in 
arthritides [19]. PWV significantly decreased by 12 months 
compared to baseline. Some other investigators also reported 
improvement of PWV upon anti-TNF therapy in RA [21, 
Table 3  Univariate and multiple analysis of determinants of vascular pathophysiology
See text for abbreviations and explanations
Dependent variable Independent variable Univariate analysis Multiple analysis
B CI 95% β p B CI 95% β p
FMD-0 CRP-0 0.076 0.004–0.148 0.318 0.040
ccIMT-0 Age 0.003 0.001–0.005 0.449 0.003 0.003 0.001–0.005 0.417 0.003
Age at diagnosis 0.003 0–0.005 0.350 0.023
RA vs AS 0.083 0.033–0.133 0.469 0.002
cNR vs cR 0.076 0.020–0.132 0.400 0.009 0.069 0.019–0.120 0.363 0.009
ccIMT-12 Age 0.005 0.002–0.007 0.477 0.001 0.005 0.002–0.007 0.526  < 0.001
Age at diagnosis 0.004 0.001–0.007 0.399 0.005
RA vs AS 0.072 0.003–0.142 0.292 0.042
CVD (history) 0.071 0.006–0.136 0.314 0.033
PWV-0 Age at diagnosis 0.062 0.009–0.114 0.351 0.023 0.056 0.008–0.104 0.321 0.022
RA vs AS 1.548 0.357–2.738 0.384 0.012
CVD (history) 1.715 0.589–2.841 0.438 0.004
Chest pain (current) 1.803 0.630–2.976 0.441 0.003 1.708 0.595–2.822 0.418 0.004
Hypertension (current) 1.481 0.296–2.665 0.371 0.016
cNR vs cR 1.391 0.078–2.704 0.321 0.038
PWV-12 Age 0.122 0.070–0.173 0.571  < 0.001 0.122 0.070–0.173 0.571  < 0.001
Age at diagnosis 0.120 0.059–0.180 0.503  < 0.001
RA vs AS 2.181 0.733–3.629 0.404 0.004
Table 4  Results of RM-ANOVA for changes from baseline to 
12  months in vascular imaging parameters in the RA + AS mixed 
population
Variable Effect F p Partial η2
FMD Treatment 4.179 0.020 0.122
Treatment × cR 3.263 0.045 0.098
ccIMT Treatment 3.958 0.024 0.102
PWV Treatment 5.993 0.007 0.130
Treatment × age 5.558 0.003 0.122
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22]. We previously reported that TNF inhibition improved 
PWV in early RA [35]. Others found no such improve-
ment, especially long-term [23, 24]. One group that found 
no change in stiffness assessed Augmentation Index (AIx) 
and not PWV [25]. However, a recent meta-analysis of 10 
studies has also suggested the beneficial effects of biolog-
ics on arterial stiffness [21]. Interestingly, while there have 
been some reports on the effects of ETN on these parameters 
[12, 16, 17], we did not find such data on CZP. Yet, CZP 
was found to alter endothelial cell gene expression including 
cell adhesion molecules [36] and attenuate the inflammatory 
state [36], activation and adhesion of endothelial cells [37].
Among vascular imaging markers, ccIMT and PWV cor-
related with each other both at baseline and after 12 months. 
We have previously found correlations between carotid ath-
erosclerosis and stiffness [29], while other groups did not 
[38]. It is possible that ccIMT and PWV are not indepen-
dently associated with each other and some other factors 
may be involved in this association [38].
Both higher ccIMT and PWV correlated with the history 
of CVD and current hypertension. Indeed, both carotid ath-
erosclerosis and arterial stiffness are associated with CVD 
[5, 33]. Moreover, as hypertension correlated with 12-month 
ccIMT, high blood pressure may aggravate consequent 
carotid atherosclerosis. It is also important, that early, non-
radiographic SpA was not associated with increased ccIMT 
indicating that there may be a window of opportunity here 
[39]. As baseline PWV correlated with most parameters 
including CV history, current chest pain, hypertension and 
cR (Table 2), assessing arterial stiffness may be a good 
screening technique. These instruments are more simple 
than assessing FMD or ccIMT in routine clinical care [5, 
31].
Clinical response to biologics may be associated with 
vascular pathophysiology. In this study, cNR patients had 
significantly higher baseline and 6-month ccIMT, as well 
as baseline PWV. cNR patients may reflect a more severe, 
difficult-to-treat subset of arthritis patients [40]. Sustained 
inflammation and clinical activity associated with clinical 
non-response to treatment drives accelerated atherosclerosis 
in RA and AS [1–3, 8]. Indeed, the reduction of myocardial 
infarction risk was observed mainly in anti-TNF responders 
[8].
Baseline FMD and baseline PWV correlated with CRP 
underscoring the effects of systemic inflammation and acute 
phase reactants on vascular pathophysiology [1, 2]. It may 
also be relevant that baseline CRP correlated with 12-month 
PWV. Higher CRP at baseline may drive vascular patho-
physiology resulting in higher arterial stiffness after one 
year, despite anti-TNF therapy. These results were confirmed 
by the univariate analysis.
The multiple analysis confirmed the association of base-
line ccIMT with age and clinical non-response. Age was 
also a predictor of 12-month ccIMT. Age also determined 
baseline and 12-month PWV. Indeed, age correlated with 
carotid atherosclerosis in some other studies [2, 29]. We 
also mentioned that the improvement of carotid atheroscle-
rosis was associated with clinical efficacy in other studies 
[18]. Baseline PWV was determined by current chest pain 
also supporting the influence of arterial stiffness on CVD 
[41]. Moreover, among stiffness parameters, PWV was a 
better predictor of CVD than augmentation index (AIx) 
[41], therefore, the assessment of PWV rather than that of 
AIx is recommended in arthritis patients [5, 29]. When RA 
and AS patients were analyzed separately, in the univariate 
analysis, the disease itself had an effect on atherosclerosis 
and stuffness. However, the multiple analysis did not confirm 
this. Therefore, the disease type may not be an independent 
predictor of vascular pathology.
In the RM-ANOVA analysis, TNF inhibition itself deter-
mined one-year changes in FMD and PWV. As described 
above, anti-TNF agents exert beneficial effects on endothelial 
function and arterial stiffness in numerous studies (reviewed 
in [7]]. FMD clearly, although sometimes transiently 
improves in most studies [7, 11–13, 15, 16], while PWV, in 
this study and some others, shows long-term improvement 
[7, 17, 21, 22]. In addition, the treatment itself exerted com-
bined effects with cR on changes in FMD. Thus, not only the 
treatment itself but also cR may predict FMD changes. As 
discussed above, improvement in FMD was associated with 
cR to biologics in other studies [12]. Clinical efficacy of a 
TNF inhibitor is usually assessed after the first 12 weeks and 
FMD is also the earliest indicator of vascular pathophysiol-
ogy [7, 28]. Moreover, anti-TNF treatment had a more pro-
nounced effect on the occurrence of CVD in responders [8]. 
Finally, treatment and age had a combined effect on changes 
in PWV. Age, also in this study, is an important determinant 
of baseline ccIMT and PWV [2, 7, 29].
Our study may certainly have some limitations. The rela-
tively small study sample may have obscured potentially 
significant results. In addition, patients with potentially posi-
tive history of CV disease were also included. RA and AS 
patients were not analyzed separately due to the relatively 
small number of patients.
In conclusion, one-year anti-TNF treatment significantly 
but transiently improved FMD improved PWV and stabi-
lized ccIMT in a mixed cohort of RA and AS patients. This 
was accompanied by clinical responses to biologics. Based 
on simple correlation analysis, the assessment of arterial 
stiffness may be a suitable screening method. Systemic 
inflammation indicated by CRP may be a determinant of 
FMD, an early indicator of vascular pathophysiology. On 
the other hand, age, history of CVD, hypertension or chest 
pain may rather be associated with arterial stiffness and 
over carotid atherosclerosis. Biologic treatment itself, with 
or without other factors, determine FMD and PWV changes 
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over 12 months. Ultrasound-based, non-invasive techniques, 
as also recommended by EULAR [1] exert additional value 
in determining CV burden and in monitoring the effects of 
anti-TNF agents on vascular pathophysiology in relation to 
clinical efficacy.
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